Author

J. Boumelha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 1 Organism:human· 1

Frequent Co-Authors

C. Moore· 4 shared E. Mugarza· 4 shared J. Downward· 4 shared M. Molina-Arcas· 4 shared S. Rana· 4 shared P. Anastasiou· 3 shared P. East· 3 shared S. de Carne Trecesson· 3 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

C. Moore

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

P. Anastasiou, C. Moore, S. Rana, A. de Castro, M. Tomaschko, J. Boumelha, E. Mugarza, C. Blaj, S. de Carne Trecesson, R. Goldstone, J. Smith, E. Quintana, M. Molina-Arcas, J. Downward

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.

bioRxiv · Jan 15, 2024Cancer Biology

CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer

J. Boumelha, A. de Castro, N. Bah, H. Cha, S. de Carne Trecesson, S. Rana, P. Anastasiou, E. Mugarza, C. Moore, R. Goldstone, P. East, K. Litchfield, S.-H. Lee, M. Molina-Arcas, J. Downward

The paper identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer through CRISPR/Cas9 screening and shows targeting COX-2 enhances immune checkpoint blockade efficacy.

bioRxiv · Apr 13, 2023Cancer Biology

Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. L. Sopena, P. East, R. Ambler, P. Anastasiou, P. R. Clavijo, K. Valand, M. Cole, M. Molina-Arcas, J. Downward

KRASG12C inhibition enhances anti-tumour immunity in immunogenic lung cancers by upregulating interferon signaling through Myc repression, but only synergizes with immune checkpoint blockade in highly immunogenic models.

bioRxiv · Oct 18, 2021Cancer Biology

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

J. Boumelha, S. de Carne Trecesson, E. Law, P. Romero-Clavijo, M. Coelho, K. Ng, E. Mugarza, C. Moore, S. Rana, D. Caswell, M. Murillo, D. Hancock, P. Argyris, W. Brown, C. Durfee, , J. Downward

This paper develops an immunogenic mouse model of KRAS-mutant lung cancer that responds to immunotherapy and reveals immune responses target endogenous retroviral antigens rather than neoantigens.

bioRxiv · Dec 22, 2020Cancer Biology